Potential and cytotoxicity of cis-platinum complex with anti-tumor activity in combination therapy

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 1, 2006, Pages 129-134

  Ho, John W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

5 fluorouracil; Anti cancer; Anti tumor; Cis platinum; Combination therapy; Cytotoxicity; Dexamethasone; Granisetron; Ligands; Metal

Indexed keywords

ANTINEOPLASTIC AGENT; LACTOFERRIN; PLATINUM COMPLEX;

ANIMAL; DRUG COMBINATION; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; NEOPLASM; PATENT; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTOFERRIN; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PATENTS AS TOPIC;

EID: 39049169184     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206775246485     Document Type: Review

References (39)

1. Shipov, V.P., Trofimov, V.A., Trofimova, N.V., Pigarev, E.S., Ivanovich Popov, A., Ivanov, V.N.: US20050080069A1 (2005).
2. Bartoli, E., Palmieri, B., Medici, A.: US20050107337A1 (2005).
3. Yamamoto T, Staples J, Wataha J, et al. Protective effects of EGCG on Salivary gland cells treated with gamma-radiation or cis-platinum (II) diammine dichloride. Anticancer Res 2004; 24: 3065-3073.
4. Dasseux, J-L. H., Oniciu, C.D.: US20040209847A1 (2004).
5. Dollner R, Dietz A, Kopun M, et al. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent. Anticancer Res 2004; 24: 2947-2951.
6. Herman, J.G., Baylin, S.B., Esteller, M.: US20040265887A1 (2004).
7. Varadhachary A, Wolf JS, O'Malley BWJr., et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 2004; 111(3): 398-403.
8. Rustum, Y.M., Cao, S., Durrani, F.: US20040180099A1 (2004).
9. Kumala S, Niemiec P, Widel M, et al. Apoptosis and clonogenic survival in three tumour cell lines exposed to gamma rays or chemical genotoxic agents. Cell Mol Biol Lett 2003; 8 (3): 655-665.
10. Papachristou E, Link KH, Schoenberg MH. Regional celiac artery infusion in the adjuvant treatment of pancreatic cancer. Anticancer Res 2003; 23 (2A): 831-834.
11. Corde S, Balosso J, Elleaume H, et al. Synchrotron photoactivation of cisplatin elicits an extra number of DNA breaks that stimulate RAD51-medicated repair pathways. Cancer Res 2003; 63(12): 3221-3227.
12. Guo CC, Zhang XB. Study on synthesis, characterization and biological activity of some new nitrogen heterocycle porphyrins. Bioorg Med Chem 2003; 11(8):1745-1751.
13. Anderson KM, Alrefai WA, Anderson CA, et al. A response of Panc-1 cells to cis-platinum, assessed with a cDNA array. Anticancer Res 2002; 22(1A): 75-82.
14. White, D., Whittle, R.R., Stowell, G.W., Whittal, L.B., Kennedy, T.: US20050096304A1 (2005).
15. Nobel SI, Burgess DH, Zhivotovsky B, et al. Mechanism of dithiocarbamate inhibition of apoptosis: Thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme. Chem Res Toxicol 1997; 10: 636-643.
16. Chinery R, Brockman JA, Peeler MO, et al. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21. sup. WAF1/C1P1 via C/EBP. beta. Nature Med 1997; 3: 1233-1241.
17. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-Kappa B J Clin Invest 2001; 107: 241-246.
18. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-Kappa B activity enhances cytotoxicity of 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003; 104: 504-511.
19. Klatt P, Sies H. Glutathione and its role in cellular functions. Free Rad Biol Med 1999; 27: 916-921.
20. Fushushima T, Takemura H, Yamashita T, et al. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line. Anticancer Res 1999; 19: 5111-5116.
21. Nakatsu N, Yoshida Y, Yamazaki K, et al. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Therap 2005; 4(3); 399-412.
22. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6(2): 129-137.
23. Martoni A, Piana E, Strocchi E, et al. Comparative crossover trial of two intravenous doses of Granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis. Anticancer Res 1998; 18: 2799-2804.
24. Schmitt E, Steyaert A, Cimoli G, et al. Bax-alpha promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells. Cell Death Differ 1998; 5(6): 506-516.
25. De La Tone M, Hao XY, Larsson R, et al. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. Anticancer Res 1993; 13: 1425-1430.
26. Bennani-Baiti IM, Lafarge FC, Herscovici J, et al. In vitro evaluation of the differential cytotoxicity of keto-C-glycosides toward normal and malignant cells. Anticancer Res 1993; 13: 467-473.
27. Koratkar R, Das UN, Sagar PS, et al. Prostacyclin is a potent antimutagen. Prostaglandins leukotrienes essent fatty acids. 1993; 48: 175-184.
28. Larsson R, Fridorg H, Csoka K, et al. Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity. Anticancer Res 1992; 12: 1581-1585.
29. Rosenberg, B. Platinum coordination complexes in cancer chemotherapy. Nature 1973; 60: 399-406.
30. Smith, M.P., Stephens, T.C.: US20040053882A1 (2004).
31. Marson, C.: WO05011661A1 (2005).
32. Hwu, P., Wang, G.: US20050063947A1 (2005).
33. McMorris, T.C., Kelner, M.J.: US6855696 (2005).
34. Uckun, F.M., Jan, S.-T.M.: US20040229935A1 (2004).
35. Cosenza, S.C., Reddy, M.U.R., Reddy, E.P.: US20040214903A1 (2004).
36. Hausheer, F.H., Dodd, T.J.: US6066668 (2000).
37. Bissery, M.-C.: US6545010 (2003).
38. Rustum, Y.M., Cao, S., Durrani, F.: US20040110838A1 (2004).
39. Bacopoulos, N.G., Chiao, J.H., Marks, P.A. et al.: WO05023179A2 (2005).